Picture loading failed.

Anti-IL6R therapeutic antibody (Pre-made Sarilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-507-1mg 1mg 3090
GMP-Bios-ab-507-10mg 10mg 21890
GMP-Bios-ab-507-100mg 100mg 148000
GMP-Bios-ab-507-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL6R therapeutic antibody (Pre-made Sarilumab biosimilar,Whole mAb)
INN Name Sarilumab
TargetIL6R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAsahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi
Conditions ApprovedRheumatoid arthritis
Conditions ActiveJuvenile rheumatoid arthritis
Conditions DiscontinuedAnkylosing spondylitis;COVID-19;Giant cell arteritis;Polymyalgia rheumatica;Uveitis
Development TechVelocImmune Mouse